Citigroup
OCUL icon

Citigroup’s Ocular Therapeutix OCUL Stock Holding History

Citigroup’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Sell
55,777
-546,140
-91% -$5.21M ﹤0.01% 3583
2025
Q4 		$7.31M Sell
601,917
-71,431
-11% -$868K ﹤0.01% 1755
2025
Q3 		$7.87M Buy
673,348
+573,504
+574% +$6.86M ﹤0.01% 1661
2025
Q2 		$927K Sell
99,844
-32,143
-24% -$252K ﹤0.01% 3240
2025
Q1 		$967K Sell
131,987
-21,100
-14% -$162K ﹤0.01% 3284
2024
Q4 		$1.31M Buy
153,087
+17,065
+13% +$166K ﹤0.01% 3158
2024
Q3 		$1.18M Buy
136,022
+71,712
+112% +$591K ﹤0.01% 3129
2024
Q2 		$440K Sell
64,310
-53,995
-46% -$333K ﹤0.01% 3477
2024
Q1 		$1.08M Buy
118,305
+99,128
+517% +$704K ﹤0.01% 2958
2023
Q4 		$85.5K Sell
19,177
-955
-5% -$2.82K ﹤0.01% 4262
2023
Q3 		$63.2K Sell
20,132
-16,013
-44% -$65.5K ﹤0.01% 4059
2023
Q2 		$187K Buy
36,145
+17,721
+96% +$105K ﹤0.01% 3923
2023
Q1 		$97.1K Buy
18,424
+10,973
+147% +$52.1K ﹤0.01% 4027
2022
Q4 		$20.9K Sell
7,451
-583
-7% -$1.93K ﹤0.01% 4572
2022
Q3 		$33K Sell
8,034
-197,517
-96% -$995K ﹤0.01% 4556
2022
Q2 		$826K Buy
205,551
+185,214
+911% +$700K ﹤0.01% 2826
2022
Q1 		$101K Sell
20,337
-12,759
-39% -$70.7K ﹤0.01% 4407
2021
Q4 		$231K Sell
33,096
-12,561
-28% -$97.5K ﹤0.01% 4281
2021
Q3 		$457K Buy
45,657
+24,613
+117% +$276K ﹤0.01% 3672
2021
Q2 		$298K Buy
21,044
+6,871
+48% +$104K ﹤0.01% 4026
2021
Q1 		$233K Sell
14,173
-7,310
-34% -$141K ﹤0.01% 3938
2020
Q4 		$445K Sell
21,483
-703
-3% -$10.4K ﹤0.01% 4308
2020
Q3 		$169K Buy
22,186
+11,319
+104% +$93.9K ﹤0.01% 4736
2020
Q2 		$91K Sell
10,867
-5,228
-32% -$34.7K ﹤0.01% 5655
2020
Q1 		$80K Buy
16,095
+4,719
+41% +$23.3K ﹤0.01% 5549
2019
Q4 		$45K Sell
11,376
-2,325
-17% -$8.08K ﹤0.01% 6394
2019
Q3 		$42K Buy
13,701
+3,876
+39% +$17.3K ﹤0.01% 6235
2019
Q2 		$43K Sell
9,825
-1,095
-10% -$4.05K ﹤0.01% 6610
2019
Q1 		$43K Sell
10,920
-8,446
-44% -$34K ﹤0.01% 6453
2018
Q4 		$78K Buy
19,366
+17,438
+904% +$96.1K ﹤0.01% 5860
2018
Q3 		$13K Sell
1,928
-11,972
-86% -$75.1K ﹤0.01% 7261
2018
Q2 		$94K Buy
13,900
+5,452
+65% +$37.5K ﹤0.01% 5783
2018
Q1 		$55K Sell
8,448
-4,446
-34% -$25K ﹤0.01% 6093
2017
Q4 		$57K Buy
12,894
+6,425
+99% +$32.8K ﹤0.01% 6085
2017
Q3 		$40K Buy
6,469
+2,273
+54% +$14.6K ﹤0.01% 6110
2017
Q2 		$39K Sell
4,196
-890
-17% -$8.61K ﹤0.01% 5950
2017
Q1 		$48K Buy
+5,086
New +$42.4K ﹤0.01% 5730
2016
Q3 		– Sell
-1,620
Closed -$8K – 7145
2016
Q2 		$8K Sell
1,620
-8,902
-85% -$88.2K ﹤0.01% 6637
2016
Q1 		$102K Buy
10,522
+5,833
+124% +$44.2K ﹤0.01% 5648
2015
Q4 		$44K Buy
4,689
+4,686
+156,200% +$50.6K ﹤0.01% 6030
2015
Q3 		$0 Sell
3
-166
-98% -$3.34K ﹤0.01% 7610
2015
Q2 		$4K Sell
169
-146
-46% -$3.62K ﹤0.01% 6888
2015
Q1 		$13K Sell
315
-29,358
-99% -$965K ﹤0.01% 6336
2014
Q4 		$698K Buy
29,673
+29,472
+14,663% +$496K ﹤0.01% 3534
2014
Q3 		$3K Buy
+201
New +$2.97K ﹤0.01% 6734

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's OCUL Position: Q1 2026 in Review

Citigroup reduced its Ocular Therapeutix (OCUL) stake by 91% in Q1 2026, selling an estimated $5.21M and leaving 55,777 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #3583.

Citigroup first reported a position in OCUL in Q3 2014 and has held it in 45 quarters since. The position peaked at $7.87M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Citigroup held 55,777 shares of Ocular Therapeutix worth $472K as of Q1 2026.
  • Citigroup sold 546,140 Ocular Therapeutix shares in Q1 2026, an estimated $5.21M.
  • Ocular Therapeutix made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3583 holding.
  • Citigroup first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 45 quarters since.
  • Citigroup's Ocular Therapeutix position peaked at $7.87M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.